Background: Previous studies have reported that hyperthyroid and hypothyroid
| INTRODUC TI ON
Menstrual cycle function is determined by a complex endocrine axis that controls the ovaries and endometrium and represents the underlying hormonal milieu of the female reproductive system.
Menstrual cycle function characteristics such as cycle length have been found to be associated with reproductive health and fertility. 1, 2 Therefore, menstrual cycle characteristics provide non-invasive markers of endocrine and reproductive health, making them useful for epidemiologic research.
The menstrual cycle is governed by a network of gonadotropins (eg, luteinizing hormone (LH) and follicle-stimulating hormone (FSH)) and sex steroid hormones (eg, oestrogens and progesterone); key constituents of the hypothalamic-pituitary-gonadal axis. This system is closely related to the hypothalamic-pituitary-thyroid axis, which controls thyroid function. 3 However, the relationship between thyroid function and female reproductive physiology is complex. Women are more likely to develop thyroid disease than men, and incidence is greatest during times of hormonal flux, such as menopause, puberty, and pregnancy, which may indicate a role of oestrogens. 4 Both hypothyroid and hyperthyroid women have been reported
to have a greater prevalence of menstrual disturbances compared with euthyroid women. [5] [6] [7] Specifically, hypothyroid women are more likely to experience oligomenorrhea and menorrhagia; 6, 8, 9 and hyperthyroid women are more likely to experience hypomenorrhea compared with euthyroid women. 5, 8 However, much of the research on this topic to date has been limited to clinic-based studies that compare women with severe forms of thyroid disease (eg, thyrotoxicosis and myxedema) with euthyroid women, and few have measured thyroid hormones. 6 In addition, many of these studies have relied upon self-reported data of menstrual cycle outcomes assessed at one time-point, and have often consolidated different outcomes together as menstrual "disturbances" or "irregularities". 8, 10 Therefore, the intricacies of the relationship between thyroid function and menstrual physiology remain unclear.
The purpose of this study was to characterise the relationship between serum thyroid hormones and specific menstrual cycle function outcomes using prospectively collected menstrual function data and urinary hormone levels across several cycles in a sample of euthyroid, premenopausal women. The associations between serum thyroid hormone concentrations and several indicators of menstrual cycle function were evaluated across multiple cycles: cycle-specific characteristics, several multi-day gonadotropin and steroid hormone measures, as well as day-specific gonadotropin and steroid hormone levels throughout the cycle.
| ME THODS

| Study population
The Michigan Polybrominated Biphenyl (PBB) Registry is a study of the long-term health outcomes of a population that was exposed to persistent organic pollutants in the early 1970s through a contamination of the food supply. 11 A subset of women in this cohort were recruited to participate in a longitudinal study on menstrual cycle function. 
| Thyroid hormones
Thyroid hormone levels were measured in serum of study participants without a history of thyroid disease and who were not currently taking thyroid-disrupting medication. Thyroid-stimulating hormone (TSH), total and free thyroxine (T 4 ), and total and free triiodothyronine (T 3 ) were analysed at the Emory Clinical
Translational Research Laboratory with the Beckman Coulter Access II chemiluminescent immunoassay analyser (Beckman Coulter, Brea, CA). Analyses were conducted as directed by the manufacturer. Daily quality control samples were run before and after all study samples, and blinded controls were run throughout. If QC samples were more than two standard deviations from the expected values, the assay was repeated. Coefficients of variation for thyroid hormone assays are shown in Table S1 .
| Menstrual cycle function protocol
Women were asked to keep daily menstrual diaries and collect first morning urine void samples every day for at least three menstrual cycles (defined as four menstrual periods or 18 weeks for oligomenorrheaic or amenorrheic women). The diaries included daily information on bleeding, menstrual cramping, stress, smoking and alcohol consumption, exercise habits, and medication use ( Figure S1 ). In termined by an algorithm examining changes in the ratio of E 1 3G to Pd3G. 12 In urine samples from women recruited in 2013-2014, E 1 3G
and Pd3G were measured every day and FSH was measured in the same 10-day window during the luteal-follicular transition, which included menses onset. Ovulatory cycles were again defined the presence of a DLT and were validated against urinary LH measurements conducted in a 10-day mid-cycle window due to the common clinical use of LH as a marker of ovulation. 
| Menstrual cycle function outcomes
Menstrual cycle function outcomes included cycle-level characteristics: cycle length, bleed length and intensity, and follicular and luteal phase lengths; multi-day hormonal outcomes calculated as 3-day geometric means (GM) of FSH, Pd3G, and E 1 3G at various times throughout the cycle (Table S2) ; and day-specific E 1 3G, Pd3G, and FSH levels throughout the cycle. Anovulation was also of interest but we did not have the power to examine this potential association.
Four cycles from 3 different women showed evidence of anovulation, which constituted 1.6% of cycles that had sufficient mid-cycle samples to detect potential ovulation.
Menses onset was defined as the first of two consecutive days of bleeding, only one of which could be spotting, and which was preceded by three consecutive days of non-bleeding or spotting. 19 Cycle length was defined as the first day of menses through the day before menses onset in the next cycle. In order to characterise within-woman variability in menstrual cycle length, we calculated the standard deviation of cycle length for each woman who contributed ≥2 cycles. Bleed intensity was the arithmetic mean of self-reported bleeding (0 = no bleeding, 1 = spotting, 2 = light, 3 = moderate, 4 = heavy) over the course of menses. The follicular phase was defined as the first day of menses through the day of ovulation. The luteal phase was the day after ovulation through the day before menses onset. 20 The hormonal outcomes were adapted from definitions proposed by Baird et al. that were shown to be related to conception.
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Maximum 3-day GMs were calculated for the follicular phase and the luteal phase only when no samples were missing during each relevant timeframe; thus sample sizes for each analysis varied by outcome (mostly due to women who missed single days of urine collection).
| Statistical analysis
Among women who did not report a history of physician-diagnosed thyroid disease and/or current thyroid medication use, we explored the distribution of each thyroid hormone in univariate analyses and by each covariate stratum. TSH was log-transformed to approximate a normal distribution.
For models where there was one outcome per cycle (cycle-level characteristics and 3-day GMs), we fit linear mixed models with a random effect for woman in order to account for the intra-individual correlations among multiple menstrual cycles per woman. We evaluated associations between each individual thyroid hormone and each menstrual cycle outcome, adjusting for age as a fixed effect.
Thyroid hormones were fit as fixed effects and were expressed continuously in all our final models, with both a linear and quadratic term to allow for flexibility with each outcome. Estimates were output for the 12.5th (low), 50th (medium) and 87.5th (high) percentile of each hormone. We also adjusted for body mass index (BMI) and smoking, but because results did not change, we present results only controlling for age. For cycle-level characteristics, we generated predicted means of each characteristic for a woman of mean age in our study (38 years). For the 3-day GM outcomes, we present comparisons (via β-coefficients) between the low (12.5th percentile) and medium (50th percentile) and high (87.5th percentile) and medium (50th percentile) thyroid hormone levels. Medium was treated as the reference because as it has been reported that both hypothyroid and hyperthyroid women experience menstrual cycle disruption compared to euthyroid women, 7 we aimed to assess impacts at the lower end as well as the higher end of each thyroid hormone distribution and compare them with median levels.
We also examined the associations between each thyroid hormone and day-specific E 1 3G, Pd3G, and FSH by fitting linear mixed models with random effects for woman and cycle to account for the nesting of days within cycles and cycles within women. E 1 3G, Pd3G, and FSH levels were adjusted for creatinine and natural logtransformed. Models for E 1 3G and Pd3G were aligned by the estimated day of ovulation ± 10 days and for E 1 3G, Pd3G, and FSH by menses onset (5 days before menses onset through cycle day 4 of the next cycle). We adjusted for age and present the predicted daily log-transformed E 1 3G, Pd3G, and FSH levels by each thyroid hormone category (low (minimum-25th percentile), medium (25th percentile-75th percentile), and high (75th percentile-maximum) over each relevant timeframe for a 38-year old (mean-aged) woman.
| RE SULTS
A total of 93 women had their blood drawn, completed a questionnaire, and collected menstrual cycle function data consisting of both urine samples and corresponding daily diaries. Seven women (7.5%) reported a previous thyroid disease diagnosis (n = 5 hypothyroid, n = 1 Hashimoto's thyroiditis, and n = 1 type not specified),
were currently taking thyroid medication, and were thus excluded from further analyses. The remaining women (n = 86) collected data for a total of 423 cycles and 65.0% of these were complete cycles (n = 275), meaning that diary data indicated a start and end to the cycle and daily menstrual function monitoring (urine samples and diary entries) occurred during the vast majority of days during the cycle. Among these 275 cycles, 64.4% had no missing urine samples;
24.0% had between 1 and 3 missing samples, and the remainder (11.6%) were missing four or more. Individual women contributed between 1 and 9 complete cycles, with a median of three complete cycles (interquartile range = 3-4). Women were between 18 and 53 years old (mean = 38 years), and a substantial proportion (40.7%) between 36 and 40 years (Table 1) . Most women had completed at least some college (84.7%), had previously been pregnant (77.9%), and were never smokers (59.3%). Table 2 shows the distribution of thyroid hormones among the 86 women never diagnosed with thyroid disease. Hormone levels for one woman (TSH = 0.06 μIU/mL, total T 4 = 12.1 μg/dL, total T 3 = 148 ng/dL, free T 4 = 1.24 ng/dL, free T 3 = 3.73 pg/mL) met the clinical definition of hyperthyroidism. All others had hormones within the euthyroid range.
Women aged 18-29 had longer cycles and follicular phases and greater cycle length variability than women in their thirties (Table   S3 ). Bleed length and intensity decreased with age. Former and current smokers had shorter cycles compared with never smokers.
Obese women had longer cycles than overweight and normal weight women. Overweight and obese women had shorter bleeds than normal weight women. Women aged 41-54 had higher FSH in the late luteal phase and early follicular phase, and lower Pd3G and E 1 3G at various timeframes across the cycle compared with younger women (Table S4) . Current smokers showed similar patterns compared with never and former smokers even after controlling for age. No consistent patterns between participant characteristics and thyroid hormones were observed (Table S5) .
Thyroid hormone levels were not associated with cycle or phase lengths and effect estimates were small (Table 3) These subtle differences in cycle length were due to variation in follicular phase length, which showed a similar pattern with free T 4 , while luteal phase lengths remained consistent across groups. Bleed length and intensity were not associated with thyroid hormone levels. Although adjusting for smoking status and BMI did not influence the effect estimates for thyroid hormones (data not shown), the predicted cycle-level characteristics were different between smoking and BMI strata, which suggests that these factors were independently associated with these menstrual cycle characteristics. In addition, results did not change when we excluded the one woman who met the clinical definition of hyperthyroidism based on her thyroid hormone assay results (data not shown). Table 4 shows the associations between thyroid hormone concentrations and the multi-day hormonal outcomes for FSH, Pd3G, and E 1 3G. Total T 4 was consistently associated with greater
Pd3G and E 1 3G across various 3-day intervals (follicular phase maximum E 1 3G and luteal phase maximum Pd3G, preovulatory E 1 3G, and mid-luteal phase Pd3G and E 1 3G). Estimated differ- concentrations had greater E 1 3G levels compared with those with lower total T 4 concentrations, although differences were smaller than for Pd3G. Free T 4 was not associated with these endocrine levels.
Total and free T 3 were also associated with both Pd3G and E 1 3G levels. In particular, higher total and free T 3 were associated with 
| COMMENT
| Principal findings
In a cohort of premenopausal euthyroid women, thyroid hormone levels were evaluated in relation to prospectively collected menstrual cycle function outcomes. To our knowledge, this is the first study to assess these relationships. Greater total T 4 was associated with higher Pd3G and E 1 3G levels throughout the cycle, and lower total T 4 was associated with lower Pd3G especially during the follicular phase. Total and free T 3 were also positively correlated with
Pd3G and E 1 3G levels at several times during the cycle. There was also a suggestion that free T 4 was associated with shorter cycle and follicular phase length. These observations were consistent when controlling for multiple potential confounders, excluding an outlier with biochemical evidence of undiagnosed hyperthyroidism, and considering hormonal outcomes as 3-day means as well as dayspecific measures.
| Interpretation
Studying the relationship between thyroid hormones and menstrual cycle function is complex because while it has been repeatedly noted in clinical studies that women with thyroid diseases experience disruption of their menstrual cycles, it is also well-understood that steroid hormones can affect thyroid hormones. For example, during pregnancy, elevated oestrogen levels lead to increased total T 4 due to thyroxine-binding globulin (TBG). 22 In this study, total T 4 was positively correlated with E 1 3G
and Pd3G throughout the cycle. Although this study was prospective in design and serum samples for measuring thyroid hormones were collected before the menstrual cycle function monitoring began, it may be possible that pre-existing steroid hormone levels led to a state of greater total T 4 concentrations, perhaps due to greater levels of TBG. Therefore, even given this longitudinal study design, it is difficult to parse out the directionality of these relationships.
One study that conducted a post-hoc analysis of a randomised controlled trial found that women on progesterone therapy had increased free T 4 after therapy compared with those who received placebo. 23 This observed correlation between progesterone and thyroxine could be due to a shared pathway within metabolic processes for increasing basal body temperature and energy expenditure.
These hormones are also both transported by albumin, although albumin carries only about 10% of circulating thyroxine, with its main transporter being TBG. 24 The positive association between total T 4 and E 1 3G is consistent with previous observations of higher plasma oestrogen levels throughout the menstrual cycle among hyperthyroid women compared with euthyroid controls. 25, 26 It has been hypothesised that this may be due to T 4 -induced increases in sex-hormone binding globulin, which leads to increases in serum levels of oestrogen and decreased clearance rates. 5, 26 However, another potential mechanism may be the increased androgen production and subsequent increased conversion of androgens to oestrogens that occurs among hyperthyroid women. 27 In this study, a TSH, thyroid-stimulating hormone; T4, thyroxine; T3, triiodothyronine. a All models control for age; in cycle length and follicular phase models, age is fit using quadratic term. 
TA B L E 2
Distribution of thyroid hormones among premenopausal women in the menstrual cycle function study (2004-2014) without self-reported thyroid disease (N = 86)
TA B L E 4 β-
| Strengths of the study
This study benefited from prospective collection of menstrual cycle function data over multiple cycles per woman. This type of monitoring has several advantages over self-report of "usual" menstrual characteristics in that it improves accuracy and precision, 19, 30 thereby reducing the likelihood of misclassification, and it incorporates a degree of within-woman variability due to observations over multiple cycles. In addition, the assessment of menstrual cycle function was comprehensive; several reproductive endocrine analytes were measured in addition to cycle characteristics. Finally, age, smoking, and BMI were related to cycle characteristics as well as several reproductive hormone levels, as reported in the literature. [31] [32] [33] [34] These observations lend additional support to the validity of the menstrual cycle function data.
| Limitations of the data
This study had some limitations as well. First, it was limited by small sample size even though there were multiple cycles per woman.
The detailed data on menstrual cycle function is reflected in a demanding study protocol, which was a contributing factor to the small number of women who participated in the study. This limited sample size prevented thorough investigation of potential effect measure modification by several characteristics that are known to affect menstrual cycle function parameters, such as age. It is theoretically possible that the associations between thyroid hormones and menstrual cycle function may differ by proximity to menopause.
Given the wide age range in this study, upon further review, two women may have been perimenopausal (one woman aged 52 years was amenorrheic during the study and another aged 54 years had consistently short cycles). However, both women showed hormonal evidence of ovulation and when excluded, were not influential observations in analyses. Future studies with larger sample sizes may consider stratifying by age to evaluate whether thyroidal impacts on menstrual cycle function may vary. Second, serum reproductive hormones were not measured; instead relying on urinary FSH and metabolites of oestrogen and progesterone. Although these are less clinically interpretable, this made it possible to obtain serial measures every day over a 3-month period, resulting in comprehensive data on menstrual cycle function.
Third, a potentially important caveat to this research is that although particular thyroid hormones were associated with certain menstrual cycle function outcomes, it is possible that these associations are not independent due to the thyroid's negative feedback loop which results in functional relationships between hormones. 35 Therefore, the observed associations with each thyroid hormone may not be isolated and, rather, the ability to detect certain associations over others is likely related to low statistical power given the limited sample size. Furthermore, because the measurement of menstrual cycle function was comprehensive and included both cycle characteristics and hormone measurements, this allowed the fitting of several models that tested associations between multiple thyroid hormones and a vast array of menstrual cycle function outcomes.
This allowed the opportunity to observe whether there was consistency among measures within and across menstrual cycles and look for overall patterns of associations between the interrelated exposures and outcomes.
| CON CLUS IONS
Thyroid hormone levels within the euthyroid range were associated with several menstrual cycle function outcomes among a sample of healthy premenopausal women. In particular, T 4 and T 3 were positively related to urinary oestrogen and progesterone metabolite levels across the menstrual cycle. This suggests that even within normal ranges, thyroid hormones may exert effects on the female reproductive system, perhaps through mechanisms involving gonadotropins and steroid hormones, specifically oestrogens and progesterone. This research contributes to furthering the understanding of the relationships between thyroid function, menstrual and reproductive physiology, and the endocrine axes that govern each.
